AEON Biopharma announced it regained compliance with NYSE American continued listing standards following an underwritten public offering that closed on July 15, 2026. The company sold 17,851,599 shares and pre-funded warrants for 24,837,008 additional shares, plus 4,696,102 shares from an over-allotment exercise on July 23, 2026. Net proceeds totaled approximately $13.6 million, with potential for up to $34.0 million more upon cash exercise of milestone warrants. This capital raise restored stockholders' equity above the $4.0 million minimum requirement, resolving deficiencies under Sections 1003(a)(i) and 1003(a)(ii). The NYSE American '.BC' indicator is expected to be removed from its trading symbol. AEON Biopharma operates in the biopharmaceutical industry, developing ABP-450 as a biosimilar to BOTOX for therapeutic use.
